Abstract 146P
Background
Studies have classified muscle-invasive bladder cancer (MIBC) into primary (initially muscle-invasive, PMIBC) and secondary subtypes (initially non-muscle-invasive but progressed, SMIBC), in which controversial survival outcomes were demonstrated. However, a relevant Chinese cohort is yet to be reported.
Methods
Patients diagnosed with PMIBC or SMIBC at West China Hospital from January 2009 to June 2019 were retrospectively included. The Kruskal–Wallis and Fisher tests were employed to compare the baseline clinicopathological characteristics. Furthermore, Kaplan–Meier curves and Cox competing proportional risk model were used to compare the PMIBC and SMIBC survival outcomes. Then, propensity score matching (PSM) was employed to reduce the bias caused by confounders and subgroup analysis was used to confirm the outcomes.
Results
A total of 405 MIBC patients were enrolled, including 286 PMIBC and 119 SMIBC patients, with a mean age of 64.66 years and 67.29 years and a mean follow-up of 27.54 months and 53.3 months, respectively. The SMIBC group had a higher proportion of older patients (17.65% vs. 9.09%), chronic disease (32.77% vs. 22.38%), and neoadjuvant chemotherapy (19.33% vs. 8.04%). Before matching, SMIBC had a lower risk of overall mortality (OM) (hazard ratios [HR] 0.60, 95% confidence interval [CI] 0.41–0.85, P = 0.005) and cancer-specific mortality (CSM) (HR 0.64, 95% CI 0.44–0.94, P = 0.022) after the initial diagnosis. However, higher risks of OM (HR 1.47, 95% CI 1.02–2.10, P = 0.038) and CSM (HR 1.58, 95% CI 1.09–2.29, P = 0.016) were observed for SMIBC once it became muscle-invasive. After PSM, the baseline characteristics of 146 patients (73 for each group) were well matched, and SMIBC was confirmed to have an increased CSM risk (HR 1.83, 95% CI 1.09–3.06, P = 0.021) than PMIBC after muscle invasion.
Conclusions
This study demonstrated that SMIBC, compared with PMIBC, had worse survival outcomes once it became muscle-invasive and suggested that specific attention should be paid to non-muscle-invasive bladder cancer with a high progression risk.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
214P - Versican G3 domain promotes myeloma cell proliferation, migration and invasion via activation of FAK/STAT3 signaling
Presenter: Nidhi Gupta
Session: Poster viewing 03
215P - Prospective observational study to evaluate impact of metabolic tumor volume on baseline 18F FDG PET/CT and molecular markers on tumor response rate in patients with diffuse large B-cell lymphoma
Presenter: Ankur Mudgal
Session: Poster viewing 03
216P - Lenalidomide maintenance after whole brain radiotherapy in relapsed/refractory primary CNS lymphoma
Presenter: Bhausaheb Bagal
Session: Poster viewing 03
217P - Role of copper levels in patients with myelodysplastic syndromes
Presenter: Revanth Boddu
Session: Poster viewing 03
218P - Prognostic role of apoptotic index in acute lymphoblastic leukemia
Presenter: Ramya Ramesh
Session: Poster viewing 03
219TiP - Randomised controlled study to compare efficacy & safety of KRd versus VRd regimens in newly diagnosed multiple myeloma using weekly schedule of generic carfilzomib
Presenter: Jasmine Porwal
Session: Poster viewing 03
233P - Cancer awareness, tobacco use and cessation among Malayali tribes, Yelagiri Hills, Tamil Nadu, India: A 8-year follow up study
Presenter: Delfin Lovelina Francis
Session: Poster viewing 03
234P - Epithelial-mesenchymal transition and cancer stem cells: Missing link in oral squamous cell carcinoma
Presenter: Selvaraj Jayaraman
Session: Poster viewing 03
235P - Evaluation of a prognostic model for head and neck cutaneous squamous cell carcinoma using a cumulative number of risk factors
Presenter: Reiichi Doi
Session: Poster viewing 03
236P - Chrono-chemotherapy combined with radiotherapy for locally advanced nasopharyngeal carcinoma: A meta-analysis
Presenter: Jianquan Yang
Session: Poster viewing 03